Role of somatostatin in the prevention of pancreatic stump-related morbidity following elective pancreaticoduodenectomy in high-risk patients and elimination of surgeon-related factors: Prospective, randomized, controlled trial

World Journal of Surgery

Volumn 27, Issue 6, 2003, Pages 709-714

  Shan, Yan Shen ^a   Sy, Edgar D ^a   Lin, Pin Wen ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SOMATOSTATIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CARCINOMA; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG EFFICACY; ELECTIVE SURGERY; FEMALE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; INCIDENCE; KIDNEY CARCINOMA; MALE; PANCREAS DISEASE; PANCREAS DUCT; PANCREAS JUICE; PANCREAS SECRETION; PANCREAS STUMP; PANCREAS STUMP RELATED COMPLICATION; PANCREATICODUODENECTOMY; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATION; PROPHYLAXIS; PROSPECTIVE STUDY; PYLORUS; RANDOMIZED CONTROLLED TRIAL; SURGEON; SURGICAL MORTALITY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LENGTH OF STAY; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PROSPECTIVE STUDIES; SOMATOSTATIN;

EID: 0042074384     PISSN: 03642313     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00268-003-6693-5     Document Type: Article

References (37)

1. Whipple AO. The rationale of radical surgery for cancer of the pancreas and ampullary region. Ann. Surg. 1941;114:612-615
2. Crist DW, Sitzmann JV, Cameron JL. Improved hospital morbidity, mortality, and survival after the Whipple procedure. Ann. Surg. 1987;206:358-365
3. Pellegrini CA, Heck CF, Raper S, et al. An analysis of the reduced morbidity and mortality rates after pancreaticoduodenectomy. Arch. Surg. 1989;124:778-781
4. Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pancreaticoduodenectomy in the 1990s: pathology, complications, outcomes. Ann. Surg. 1997;226:248-260
5. Peter JH, Carey LC. Historical review of pancreaticoduodenectomy. Am. J. Surg. 1991;16:219-225
6. Singh SM, Longmire WP, Reber HA. Surgical palliation for pancreatic cancer. Ann. Surg. 1990;212:132-139
7. Trede M, Schwall G. The complications of pancreatectomy. Ann. Surg. 1988;207:39-47
8. Moosa AR. Surgical treatment of chronic pancreatitis: an overview. Br. J. Surg. 1987;74:661-667
9. Schirmer WJ, Rossi RL, Braasch JW. Common difficulties and complications in pancreatic surgery. Surg. Clin. North Am. 1991;71:1391-1417
10. Piorkowski RJ, Blievernicht SW, Lawrence W, et al. Pancreatic and periampullary carcinoma: experience with 200 patients over a 12-year-period. Am. J. Surg. 1982;143:189-193
11. Di Carlo VD, Chiesa R, Pontiroli AE, et al. Pancreatoduodenectomy with occlusion of the residual stump by neoprene injection. World J. Surg. 1989;13:105-111
12. Bassi C, Falconi M, Pederzoli P. Role of somatostatin and somatostatin analogues in the treatment of gastrointestinal diseases: prevention of complications after pancreatic surgery. Gut 1994;35:S20-S22
13. Jenkins SA. Emerging Differences in the Therapeutic Efficacy of Somatostatin and Octreotide in Gastroenterology and Surgery, Hong Kong, MediMedia Asian Publication, 1996;14
14. Prinz RA, Pickleman J, Hoffman JP. Treatment of pancreatic fistula with a somatostatin analogue. Am. J. Surg. 1988;155:36-42
15. Petrin P, Antoniutti M, Zaramella D, et al. Effect of octreotide acetate on pancreatic exocrine and endocrine functions after pancreaticoduodenal resection. Eur. Surg. Res. 1995;27:371-378
16. Lin PW, Lee JC, Lee PC, et al. A simple, secure, and universal pancreaticojejunostomy following pancreaticoduodenectomy. HPB Surg. 1997;10:305-310
17. Hamanaka Y, Suzuki T. Total pancreatic duct drainage for leakproof pancreaticojejunostomy. Surgery 1994;115:22-26
18. Raptis S, Schlegel W, Lehmann E, et al. Effects of somatostatin on the exocrine pancreas and the release of duodenal hormone. Metabolism. 1978;27:1321-1328
19. Heintges T, Luthen R, Niederau C. Inhibition of exocrine pancreas secretion by somatostatin and its analogues. Digestion 1994;55:1-9
20. Klempa J, Schwedes U, Usadel KH. Verhutung von postoperativen pankreatitischen koomplikationen nach duodenopankreatetomie durch somatostatin. Chirurgia (Bucur). 1979;50:427-431
21. Gouillat C, Chipponi J, Partensky C, et al. Effects of somatostatin infusion on the pancreatic remnant secretions after pancreatoduodenectomy. Hepatogastroenterology. 1998;45:198
22. Gouillat C. Somatostatin for the prevention of complications following pancreaticoduodenectomy. Digestion 1999;60:59-63
23. Büchler M, Friess H, Klempa I, et al. Role of octreotide in the prevention of postoperative complications following pancreatic resection. Am. J. Surg. 1992;163:125-136
24. Montoris M, Zago M, Mosca F, et al. Efficacy of octreotide in the prevention of pancreatic fistula after elective pancreatic resections: a prospective, controlled, randomized clinical trial. Surgery 1995;117:26-31
25. Pederzoli P, Bassi C, Falconi M, et al. Efficacy of octreotide in the prevention of complications after elective pancreatic surgery. Br. J. Surg. 1994;81:265-269
26. Habib E, Elhadad A, Fourtanier G, et al. Place de l'octréotide dans la prévention des complications chirurgicales après pancréatectome. étude contrôlée multicentrique. Ann. Chir. 1998;52:671-672
27. Lowy AM, Lee TE, Pisters PWT, et al. Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy. Ann. Surg. 1997;226:632-641
28. Yeo CJ, Cameron JL, Lillemoe KD, et al. Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial. Ann. Surg. 2000;232:419-429
29. Bartoli FG, Arnone GB, Ravera G. Pancreatic fistula and relative mortality in malignant disease after pancreaticoduodenectomy. Review and statistical meta-analysis regarding 15 years of literature. Anticancer Res. 1991;11:1831-1848
30. Friess H, Bordih K, Ebert M, et al. Inhibition of pancreatic secretion under long-term octreotide treatment in humans. Digestion 1994;55:10-15
31. Londong W, Angerer M, Kutz K, et al. Diminishing efficacy of octreotide (SMS 201-995) on gastric functions of healthy subjects during one-week administration. Gastroenterology 1989;96:713-722
32. Ho LT, Chen RL, Chou TY, et al. Pharmacokinetics and effects of intravenous infusion of somatostatin in normal subjects - a two-compartment open model. Clin. Physiol. Biochem. 1986;4:257-267
33. Lin PW, Lin YJ. Prospective randomized comparison between pylorus-preserving and standard pancreaticoduodenectomy. Br. J. Surg. 1999;86:603-607
34. Yeo CJ, Cameron JL, Maher MM, et al. A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. Ann. Surg. 1995;222:580-592
35. Hamanaka Y, Nishihara K, Hamasaki T, et al. Pancreatic juice output after pancreaticoduodenectomy in relation to pancreatic consistency, duct size, and leakage. Surgery 1996;119:281-287
36. Ishikawa O, Ohigashi H, Imaoka S, et al. Concomitant benefit of preoperative irradiation in preventing pancreas fistula formation after pancreaticoduodenectomy. Arch. Surg. 1991;126:885-889
37. Van Hee R, De Laet I, Salgado R, et al. The influence of somatostatin on postoperative outcome after elective pancreatic surgery. Acta Chir. Belg. 1998;98:62-65